港股异动丨金斯瑞生物科技涨超4% 传奇生物旗下CAR-T产品第三季度销售额达5.24亿美元

Core Viewpoint - Kingsoft Biotech (1548.HK) has seen a significant stock price increase of 4.71% to HKD 16.67, with a year-to-date gain of nearly 70%, outperforming the market index which has risen approximately 30% during the same period [1] Group 1: Company Performance - Kingsoft Biotech's stock price has increased by 4.71% to HKD 16.67 during intraday trading [1] - The company has achieved a year-to-date stock price increase of nearly 70% [1] - The performance of Kingsoft Biotech has outpaced the Hang Seng Index, which has risen about 30% in the same timeframe [1] Group 2: Business Developments - Kingsoft Biotech announced that its affiliate, Legend Biotech Corporation, submitted a 6-K form to the U.S. Securities and Exchange Commission on October 14, 2025 [1] - The report indicated that CARVYKTI® generated trade sales net revenue of approximately USD 524 million for the quarter ending September 30, 2025, under a collaboration and licensing agreement with Janssen Biotech, Inc. established on December 21, 2017 [1]